NCT03106545 is a Phase 2 clinical trial of Liposome bupivacaine in Hallux Valgus (Bunions), sponsored by Catherine Vandepitte, M.D..

Who is sponsoring NCT03106545?

NCT03106545 is sponsored by Catherine Vandepitte, M.D..

What drugs are being tested in NCT03106545?

Interventions in NCT03106545: Liposome bupivacaine.

What condition does NCT03106545 study?

NCT03106545 studies Hallux Valgus (Bunions).

Is NCT03106545 still recruiting?

NCT03106545 is currently completed. Last updated 11 September 2020.

Last reviewed 2020-09-11 · How we verify

NCT03106545

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liposome Bupivacaine for ANKLE Blocks

Completed Phase 2 Last updated 11 September 2020

What this trial tests

Phase 2 trial testing Liposome bupivacaine in Hallux Valgus (Bunions) in 40 participants. Completed in 31 October 2017.

Timeline

2 January 2017

Primary endpoint
26 June 2017

31 October 2017

Quick facts

Lead sponsor	Catherine Vandepitte, M.D.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	40
Start date	2 January 2017
Primary completion	26 June 2017
Estimated completion	31 October 2017
Sites	1 location across Belgium

Drugs / interventions tested

Liposome bupivacaine — full drug profile →

Conditions studied

Hallux Valgus (Bunions) — all drugs for Hallux Valgus (Bunions) →

Sponsor

Catherine Vandepitte, M.D. — full company profile →

Who can join

Adults 18 to 65, any sex, with Hallux Valgus (Bunions). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Postoperative analgesia for hallux valgus surgery (bunionectomy) is inconsistent and may even result in rebound pain when the (ankle) blocks wear off. It is hypothesized that the mixture of bupivacaine and liposome bupivacaine increases the extent and duration of postoperative analgesia and decreases opioid consumption as compared to bupivacaine alone or to general anesthesia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Catherine Vandepitte, M.D. trials

Trials by the same sponsor.

NCT03106519 — Liposome Bupivacaine for WRIST Blocks · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03106545 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Catherine Vandepitte, M.D.
Last refreshed: 11 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03106545.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing